Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;11(4):329-337.
doi: 10.1080/17474124.2017.1292851. Epub 2017 Feb 16.

Cannabinoids for Treating Inflammatory Bowel Diseases: Where Are We and Where Do We Go?

Free PMC article

Cannabinoids for Treating Inflammatory Bowel Diseases: Where Are We and Where Do We Go?

Carina Hasenoehrl et al. Expert Rev Gastroenterol Hepatol. .
Free PMC article


Fifty years after the discovery of Δ9-tetrahydrocannabinol (THC) as the psychoactive component of Cannabis, we are assessing the possibility of translating this herb into clinical treatment of inflammatory bowel diseases (IBDs). Here, a discussion on the problems associated with a potential treatment is given. From first surveys and small clinical studies in patients with IBD we have learned that Cannabis is frequently used to alleviate diarrhea, abdominal pain, and loss of appetite. Single ingredients from Cannabis, such as THC and cannabidiol, commonly described as cannabinoids, are responsible for these effects. Synthetic cannabinoid receptor agonists are also termed cannabinoids, some of which, like dronabinol and nabilone, are already available with a narcotic prescription. Areas covered: Recent data on the effects of Cannabis/cannabinoids in experimental models of IBD and in clinical trials with IBD patients have been reviewed using a PubMed database search. A short background on the endocannabinoid system is also provided. Expert commentary: Cannabinoids could be helpful for certain symptoms of IBD, but there is still a lack of clinical studies to prove efficacy, tolerability and safety of cannabinoid-based medication for IBD patients, leaving medical professionals without evidence and guidelines.

Keywords: Cannabinoids; Cannabis; Crohn’s disease; dronabinol; inflammatory bowel disease; medical marijuana; nabilone; nabiximols; ulcerative colitis.


Figure 1.
Figure 1.
A schematic overview of cannabinoid receptors, cannabinoid-responsive non-cannabinoid receptors, their ligands and degrading enzymes of the endocannabinoid system as described in murine IBD. 2-AG, 2-arachidonoylglycerol; AEA, anandamide; CB, cannabinoid receptor; CBD, cannabidiol; FAAH, fatty acid amide hydrolase; GPR55, G protein-coupled receptor 55; NAAA, N-acylethanolamine-hydrolyzing acid amidase; PEA, palmitoylethanolamide; PPARs, peroxisome proliferator-activated nuclear receptors; THC, Δ9-tetrahydrocannabinol; TRPV1, transient receptor potential of vanilloid-type 1.

Similar articles

See all similar articles

Cited by 13 articles

See all "Cited by" articles


    1. Cosnes J, Gowerrousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–1794. - PubMed
    1. Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol. 2010;45(6):571–583. - PubMed
    1. Hasenoehrl C, Taschler U, Storr M, et al. The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil. 2016;28(12):1765–1780. - PMC - PubMed
    2. • Good overview of the endocannabinoid system in the gastrointestinal tract and its role in functional and inflammatory bowel disorders as well as in colon cancer.

    1. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010;126(1):21–38. - PubMed
    1. Schicho R, Storr M. Targeting the endocannabinoid system for gastrointestinal diseases: future therapeutic strategies. Expert Rev Clin Pharmacol. 2010;3(2):193–207. - PubMed

MeSH terms